ORMP
NASDAQ · Pharmaceuticals
Oramed Pharmaceuticals Inc
$3.95
-0.03 (-0.75%)
Financial Highlights (FY 2026)
Revenue
1.91M
Net Income
61.30M
Gross Margin
0.6%
Profit Margin
3,202.5%
Rev Growth
-9.5%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 0.6% | 0.6% | 43.8% | 43.8% |
| Operating Margin | -754.4% | -679.0% | 19.2% | 21.2% |
| Profit Margin | 3,202.5% | 3,042.4% | 17.1% | 21.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 1.91M | 2.11M | 32.28M | 32.90M |
| Gross Profit | 12.4K | 13.7K | 14.13M | 14.40M |
| Operating Income | -14,426,006 | -14,349,475 | 6.20M | 6.98M |
| Net Income | 61.30M | 60.98M | 5.51M | 7.09M |
| Gross Margin | 0.6% | 0.6% | 43.8% | 43.8% |
| Operating Margin | -754.4% | -679.0% | 19.2% | 21.2% |
| Profit Margin | 3,202.5% | 3,042.4% | 17.1% | 21.6% |
| Rev Growth | -9.5% | -9.5% | +15.3% | -1.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 16.15M | 14.75M |
| Total Equity | — | — | 85.85M | 90.16M |
| D/E Ratio | — | — | 0.19 | 0.16 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -14,230,220 | -14,941,101 | 8.62M | 9.08M |
| Free Cash Flow | — | — | 3.23M | 4.24M |